Nov. 8 at 7:06 PM
🎯 Needham Maintains Buy Rating on
$AMPH, Lowers Price Target to
$34 📉
✅ Amphastar Pharmaceuticals reported Q3 adjusted EPS of
$0.93, exceeding analyst estimates of
$0.83.
✅ Q3 revenue came in at
$191.84 million, surpassing the consensus estimate of
$185.23 million.
✅ Anticipated decrease in glucagon revenues is expected due to new competitors entering the market in late 2024 and early 2025.
✅ Lower-than-expected price levels, stemming from increased market competition, are likely to negatively impact future financial performance.
